Biocept Inc (NASDAQ:BIOC) (FRA:B003) will host a webinar featuring leading neuro-oncologists to discuss the use of its proprietary cerebrospinal fluid (CSF) assay for diagnosing and managing tumors that have metastasized to the central nervous system (CNS), including the brain or spinal column.
The company said its CSF assay provides enhanced sensitivity compared with CSF cytology, the current standard-of-care, and has the added advantage of identifying actionable molecular targets for use in treatment decisions while providing quantitative information needed for assessing treatment response and monitoring disease progression.
READ: Biocept posts first-ever quarterly profit and balloons 4Q revenue to $18.5M on strength of coronavirus testing
“Our goal is to establish our CSF assay as the new standard of care for the diagnosis of patients with suspected cancer metastasis to the CNS under National Comprehensive Cancer Network guidelines,” said Dr Michael Dugan, Biocept’s chief medical officer, in a statement Thursday.
“We have already gained substantial interest among neuro-oncologists and other cancer specialists from nearly two dozen leading academic institutions across the country. Most of these physicians have already ordered our CSF assay, with many becoming repeat users."
Dr Dugan added: “The CSF assay addresses a high unmet clinical need as current diagnostic tools for patients with brain metastases are inadequate or imprecise for assessing therapy response; however, many therapies are now available that offer substantial promise for improved survival and resolution of symptoms. Between 10% and 30% of adult patients with cancer, depending on the type, will develop brain metastases. We estimate this market opportunity at more than $1 billion annually.”
The webinar will be held on April 8 at 12 pm ET. Participants can pre-register or register at the webinar start time here. The webinar also will be available live and archived at https://ir.biocept.com/.
Contact the author: email@example.com
Follow him on Twitter @PatrickMGraham